Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$57.58M$57.58Mderived+94.1% vs Q4 2024 Net Income-$21.15M-$21.15MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$49,937,000+93.2% Operating Incomederived-$5,928,000N/M Operating Cash Flowderived-$5,001,000N/M Free Cash Flowderived-$5,088,000N/M Margins · derivedGross margin86.7%−0.4 pt vs Q4 2024
Operating margin-10.3%+190.0 pt vs Q4 2024
Net margin-36.7%+214.3 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end